Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...

Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...

CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new ...

Beam Therapeutics (NASDAQ:BEAM) announced on Tuesday that it received U.S. FDA's orphan drug designation for its cell therapy, BEAM-101, to treat sickle cell disease. With its orphan drug designation, ...

Eilersen has announced it is releasing a new series of digital load cells in a hygienic (aseptic) design. The new product is targeted at food and pharmaceutical industry customers and is used for ...

Beam Therapeutics (BEAM) just released new BEACON trial data on its sickle cell therapy risto cel, showing durable hemoglobin F gains, lower hemoglobin S, and anemia resolution that help explain the ...

CAMBRIDGE - Beam Therapeutics Inc. (NASDAQ:BEAM) released updated clinical data from 31 patients treated with its experimental sickle cell disease (SCD) gene therapy, showing sustained benefits ...